- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06023615
MITIGAAT: Multifaceted Intervention To Improve Graft Outcome Disparities in African American Kidney Transplants
Multifaceted Intervention To Improve Graft Outcome Disparities in African American Kidney Transplants (MITIGAAT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The overarching hypothesis for MITIGAAT is that late non-adherence and suboptimal control of diabetes and hypertension are more common in African American kidney recipients and are major contributors to health disparities. A multimodal intervention that addresses these issues will significantly reduce disparities. This hypothesis will be tested through a rigorously conducted, prospective, 2-year randomized controlled trial in 190 kidney transplant recipients from MUSC, designed to assess the following aims:
Aim 1. Determine the impact of this multilevel health services intervention on achieving improved adherence to tacrolimus, measured using tacrolimus trough variability and time in range in the treatment vs control arm.
Aim 2. Determine the impact of this multilevel health services intervention on blood pressure (BP) and glucose control (in those with DM) in the treatment vs control arm.
Aim 3. Conduct a cost-benefit analysis (CBA), assessing the estimated hospitalization and ED visit costs in the intervention arm vs the control arm and compare this to the costs needed to deliver the intervention.
Aim 4. Compare the incidence of acute rejection, graft loss and death in the intervention patients vs. a large contemporary national cohort of Veteran kidney transplant recipients while also assessing racial disparities for these health outcomes
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- Medical University of South Carolina
-
Contact:
- David Taber, PharmD, MS
- Phone Number: 843-792-2724
- Email: taberd@musc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥18 years of age
- ≥2 years post-kidney transplant
Exclusion Criteria:
- Non-kidney transplant recipient (liver, lung, heart, intestine, pancreas, bone marrow)
- Not capable of measuring own BP and glucose in those with diabetes
- Not capable of using mobile health application after adequate training
- Not capable of speaking, hearing, and reading English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Group
Usual Care + mHealth/Telehealth
|
In the interventional group, the subject would receive the standard care that is provided to all post-transplant kidney recipients plus an additional remote monitoring system and follow-up by utilizing an app known as the mHealth app/dashboard.
This app is integrated with home-based monitoring of blood pressures, glucoses, and pharmacist-led scheduled televisits.
|
No Intervention: Control Group
Usual Care + Attention Control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication Adherence
Time Frame: 2 Years
|
Medication adherence will be measured by using tacrolimus trough concentration variability, which is a validated proxy measure of medication adherence.
This is defined as the intrapatient tacrolimus concentration coefficient of variation (CV): standard deviation divided by the mean for each patient.
All outpatient true trough tacrolimus levels drawn will be used to calculate the tacrolimus CV.
This will be assessed every 3 months, which aligns with the minimum lab draw schedule for kidney transplant recipients at out center.
This will be analyzed using repeated measures methodology, estimating efficacy effect size using the time*treatment interaction term and disparity using the time*treatment*race interaction term.
|
2 Years
|
Blood Pressure
Time Frame: 2 Years
|
Blood pressure control will be defined as the mean of all systolic BPs checked by patients at home and the transplant center (ambulatory measures).
Patients with a mean of SBP ≤140 mmHg will be considered controlled.
We will aggregate and assess blood pressure levels every month (25 total); analyzed using repeated measures (time*treatment and disparity using the time*treatment*race interaction term).
|
2 Years
|
Glucose Control
Time Frame: 2 Years
|
Glucose control is defined as the mean measure of all glucoses (random or fasting).
Those with DM and a mean random glucose ≤160 mg/dL will be considered to controlled.
We will aggregate and assess glucose levels every month (25 total); analyzed using repeated measures (time*treatment and disparity using the time*treatment*race interaction term).
|
2 Years
|
Cost-Benefit Analysis
Time Frame: 2 Years
|
Conduct a cost-benefit analysis (CBA), assessing the estimated hospitalization and ED visit costs in the intervention arm vs the control arm and compare this to the costs needed to deliver the intervention.
|
2 Years
|
Acute Rejection
Time Frame: 2 Years
|
This is defined as the proportion of patients in each arm with a renal allograft biopsy showing at least grade 1A rejection by Banff criteria.
Per usual care practices, all patients are required to have biopsy confirmation of rejection episodes within 24 hours of onset of treatment for acute rejection.
It is standard care that all kidney allograft biopsies performed for transplant recipients occur at the transplant center (study institution).
Biopsies will be read by a blinded local pathologist, as usual care.
This will be assessed using time to event analyses..
|
2 Years
|
Graft Failure
Time Frame: 2 Years
|
This is defined as the proportion of patients in each arm with graft failure, which is a composite outcome of either return to chronic dialysis, nephrectomy, re-transplant, or death.
The timing and cause of each graft loss will be recorded for comparative analysis.
|
2 Years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Pro00127666
- 1R01DK134326-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Medication Adherence
-
NYU Langone HealthRobert Wood Johnson Foundation; New York City Health and Hospitals CorporationCompletedMedication Adherence | Medication ErrorsUnited States
-
Vanderbilt University Medical CenterCompletedAdherence, Medication | Nonadherence, MedicationUnited States
-
Universidad Autonoma de Baja CaliforniaCompletedMedication Adherence | Medication ComplianceMexico
-
Universiti Putra MalaysiaCompletedMedication Adherence | Adherence, TreatmentPakistan
-
University Hospital, Basel, SwitzerlandUniversity of BaselCompletedPolymedication-Check With Insight in Patients' Medication Organisation and Comprehension of GenericsMedication Adherence | Medication Therapy ManagementSwitzerland
-
Cliniques universitaires Saint-Luc- Université...RecruitingAdherence, MedicationBelgium
-
Northwell HealthNational Institute on Aging (NIA)RecruitingMedication AdherenceUnited States
-
Swedish Medical CenterNational Institute of Mental Health (NIMH); University of Washington; University...Recruiting
-
Northwell HealthToronto Dominion BankCompletedMedication AdherenceUnited States
-
Akdeniz University HospitalCompleted
Clinical Trials on mHealth app/dashboard
-
Tulane UniversityOsaka University; Centre Suisse de Recherches Scientifiques en Cote d'Ivoire; Institut Pasteur of Cote d'Ivoire and other collaboratorsRecruiting
-
Hospital Universitari de BellvitgeVifor PharmaActive, not recruiting
-
University of NicosiaCompletedTelemedicine | Pressure Ulcer | CaregiversCyprus
-
St. Louis UniversityNational Center for Responsible GamingNot yet recruiting
-
Washington University School of MedicineWashington University Institute of Clinical and Translational SciencesCompletedAnxiety Disorders | Adolescent DepressionUnited States
-
University of UtahHitachi, Ltd.CompletedDiabetes Mellitus, Type 2 | Diabetes MellitusUnited States
-
Universitaire Ziekenhuizen KU LeuvenOslo University Hospital; University of Bordeaux; KU Leuven; University College... and other collaboratorsNot yet recruitingGeriatrics | Medical Oncology | Critical Pathways | Digital TechnologyBelgium
-
Ohio State UniversityDexCom, Inc.; Agency for Healthcare Research and Quality (AHRQ)Not yet recruitingPregnancy, High Risk | Pre-Gestational Diabetes | Pregnancy in Diabetic | Type2diabetesUnited States
-
University of California, DavisCompletedPsychosis | Clinical High Risk for PsychosisUnited States
-
Eindhoven University of TechnologyCompletedLifestyle | Lifestyle, Healthy | Lifestyle Risk Reduction | Lifestyle, SedentaryBelgium